Interactions of the Opioid and Cannabinoid Systems in Reward: Insights from Knockout Studies

Total Page:16

File Type:pdf, Size:1020Kb

Interactions of the Opioid and Cannabinoid Systems in Reward: Insights from Knockout Studies REVIEW ARTICLE published: 05 February 2015 doi: 10.3389/fphar.2015.00006 Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies Katia Befort* CNRS, Laboratoire de Neurosciences Cognitives et Adaptatives – UMR7364, Faculté de Psychologie, Neuropôle de Strasbourg – Université de Strasbourg, Strasbourg, France Edited by: The opioid system consists of three receptors, mu, delta, and kappa, which are Dominique Massotte, Institut des activated by endogenous opioid peptides (enkephalins, endorphins, and dynorphins). The Neurosciences Cellulaires et Intégratives, France endogenous cannabinoid system comprises lipid neuromodulators (endocannabinoids), enzymes for their synthesis and their degradation and two well-characterized receptors, Reviewed by: Fernando Berrendero, Universitat cannabinoid receptors CB1 and CB2. These systems play a major role in the control of Pompeu Fabra, Spain pain as well as in mood regulation, reward processing and the development of addiction. Krisztina Monory, University Medical Both opioid and cannabinoid receptors are coupled to G proteins and are expressed Centre of the Johannes Gutenberg University, Germany throughout the brain reinforcement circuitry. Extending classical pharmacology, research using genetically modified mice has provided important progress in the identification of the *Correspondence: Katia Befort, CNRS, Laboratoire de specific contribution of each component of these endogenous systems in vivo on reward Neurosciences Cognitives et process. This review will summarize available genetic tools and our present knowledge on Adaptatives – UMR7364, Faculté de the consequences of gene knockout on reinforced behaviors in both systems, with a focus Psychologie, Neuropôle de Strasbourg – Université de on their potential interactions. A better understanding of opioid–cannabinoid interactions Strasbourg, 12, rue Goethe, F -67000 may provide novel strategies for therapies in addicted individuals. Strasbourg, France Keywords: opioid, cannabinoid, G protein-coupled receptors, reward, genetically modified mice e-mail: [email protected] INTRODUCTION Among illicit drugs, opiate and cannabinoid derivatives are Drug abuse often leads to a complex pharmaco-dependent state highly abused in Europe. Morphine-like opiates are powerful which is defined by the term addiction. Addiction is consid- analgesics and currently represent the major therapeutic reme- ered as a neuropsychiatric disease. It develops from an initial dies for the treatment of severe pain. They are also abused recreational drug use, evolves toward compulsive drug-seeking for their recreational euphoric effects. In Europe, 1.3 million behavior and excessive drug-intake with the appearance of nega- people are addicted to heroin, the primary drug for which tive emotional states such as anxiety or irritability when the drug treatment requests are sought. Cannabis is the most worldwide is not accessible, and uncontrolled intake reaching a stage where consumed drug of abuse, with THC being the most abun- the drug interferes with daily activities, despite the emergence dant active constituent found in the various preparations of of adverse consequences (Leshner, 1997; Everitt and Robbins, the drug. More than 73 million European citizens have used 2005; Robinson and Berridge, 2008; Koob, 2009). This patholog- cannabis in the last year and it is estimated that about 7% of ical process develops in 15–30% of casual drug users and several cannabis users has become dependent on this drug. There is also factors may explain individual’s vulnerability to addiction, includ- a high prevalence of users who seek treatment for dependence on ing genetic, psychological and environmental factors (Swendsen it (http://www.emcdda.europa.eu/publications/edr/trends-develo and Le Moal, 2011; Belin and Deroche-Gamonet, 2012; Pattij pments/2014). Interestingly, new derivatives of these abused drugs and De Vries, 2013; Saunders and Robinson, 2013). Addiction are invading the market, notably through internet. Fentanyl is a major threat to public health and represents a societal prob- derivatives as new opioid drugs and synthetic cannabimimetics, lem especially in developed countries and the economic cost it also known as “spices,” are becoming more and more popular entails (investments in research, treatment and prevention) is (Fattore and Fratta, 2011). These abusive substances interact with considerable (Gustavsson et al., 2011). two neuromodulator sytems, the opioid and the endocannabinoid systems. Abbreviations: 2-AG, 2-arachidonoylglycerol; AEA, anandamide, N-arachidonoyl- ethanolamide; CB1, type 1 cannabinoid receptor; CB2, type 2 cannabi- THE OPIOID SYSTEM noid receptor; cKO, conditional knockout mice; CPA, conditioned place The opioid system consists of endogenous opioid peptides aversion; CP 55,940, (1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]- (enkephalins, endorphins, and dynorphins) from precursors 4-(3-hydroxypropyl)cyclohexan-1-ol; CPP, conditioned place preference; CPu, caudate putamen; DA, dopamine; DAGL, diacylglycerol lipase; FAAH, (Penk, Pdyn, and Pomc) which activate three opioid receptors, fatty acid amide hydrolase; G protein, guanine nucleotide binding pro- namely mu, delta, and kappa (Kieffer, 1995). The three mem- tein; GABA, c-aminobutyric acid; GPCR, G protein coupled receptor; brane receptors, cloned in the early nineties (Evans et al., 1992; KO, knockout; MGL, monoacylglycerol lipase; NAPE-PLD, N-acyl phos- Kieffer et al., 1992; Simonin et al., 1994, 1995; Mestek et al., 1995) phatidylethanolamine phospholipase D; THC, Delta-9-tetrahydrocannabinol; WIN 55,212-2, 2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]- are GPCR with coupling to Gi/Go proteins, of which the 3D 1,4-benzoxazin-yl-1-naphtalenylmethanone mesylate; WT, wild-type. structure was recently resolved (see Filizola and Devi, 2014). www.frontiersin.org February 2015 | Volume 6 | Article 6 | 1 Befort Opioid and cannabinoid systems interaction in reward Opioid receptors and endogenous opioid peptides are largely energy balance, modulation of pain response, with processing of expressed throughout the nervous system, noticeably within areas central and peripheral pain signals, learning and memory, reward of the neurocircuitry of addiction associated with reward, motiva- and emotions. It has also been shown to be involved in neuroge- tion, or learning and stress (Mansour et al., 1995; Le Merrer et al., nesis and would play a neuroprotective role in some pathological 2009; Koob and Volkow, 2010; Erbs et al., 2014). Besides its key conditions (for recent reviews see Gardner, 2005; Solinas et al., role in many aspects of addition (Lutz and Kieffer, 2013a), the 2008; Maldonado et al., 2011; Zanettini et al., 2011; Panagis et al., opioid system also plays a part in a diverse range of physiological 2014; Piomelli, 2014). Distribution of the two receptors in the functions including nociception, mood control, eating behavior, central and peripheral system is rather different (Pertwee, 2010). or cognitive processes (Contet et al., 2004; Pradhan et al., 2011; Indeed, CB1 is highly abundant in the central nervous system in Stein, 2013; Bodnar, 2014; Nogueiras et al., 2014). areas involved in reward, regulation of appetite and nociception (see Figure 1) while CB2 was initially described as a peripheral THE ENDOCANNABINOID SYSTEM receptor (Maldonado et al., 2006, 2011; Mackie, 2008). Recent The endocannabinoid system is a neuromodulatory system con- studies have proposed a low but significant expression of this sisting of two well characterized transmembrane receptors coupled receptor in several brain structures including striatum, hippocam- to G protein (Gi/Go), CB1, and CB2 cloned in the 1990’s (Mat- pus, and thalamus (Wotherspoon et al., 2005; Gong et al., 2006; suda et al., 1990; Munro et al., 1993). The endogenous ligands Onaivi et al., 2006) and more recently into ventral tegmental area are lipid neuromodulators, the main ones being AEA and 2-AG. neurons (Zhang et al., 2014). Only few data are therefore available Both are synthesized from phospholipid precursors and act locally for the CB2 receptor in central function but growing evidence sug- as retrograde regulators of synaptic transmission throughout the gest a role in addictive processes, with an implication in cocaine, central nervous system. These lipids are released by postsynaptic nicotine, or ethanol effects (Xi et al., 2011; Ignatowska-Jankowska neurons and mainly activate presynaptic cannabinoid receptors to et al., 2013; Navarrete et al., 2013; Ortega-Alvaro et al., 2013). To transiently or persistently suppress transmitter release from both our knowledge, no data is available thus far concerning a potential excitatory and inhibitory synapses (recently reviewed in Ohno- role of CB2 in opioid mediated responses. Interestingly, other Shosaku and Kano, 2014). Multiple pathways are involved in AEA non-CB1 and non-CB2 receptors have been proposed to interact biosynthesis with several still not fully characterized enzymes. with endocannabinoids like the orphan GPCR GPR55 or a channel AEA can be generated from the membrane phospholipid precur- vanilloid TRPV1 recognizing capsaicin. These interactions could sor N-arachidonoyl phosphatidylethalonamine (NAPE) through a potentially explain some pharmacology of cannabis that cannot two-step process with first a calcium-dependent transacylase fol- be accounted for by CB1 and CB2 activation, but further studies lowed by a phospholipase
Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Oral Drug Delivery System Comprising High Viscosity
    (19) & (11) EP 1 575 569 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/52 (2006.01) 29.09.2010 Bulletin 2010/39 (86) International application number: (21) Application number: 03799943.0 PCT/US2003/040156 (22) Date of filing: 15.12.2003 (87) International publication number: WO 2004/054542 (01.07.2004 Gazette 2004/27) (54) ORAL DRUG DELIVERY SYSTEM COMPRISING HIGH VISCOSITY LIQUID CARRIER MATERIALS ORALE DARREICHUNGSFORM MIT FLÜSSIGEN HOCHVISKOSEN TRÄGERSYSTEMEN FORME D’ADMINISTRATION ORALE DE MEDICAMENTS COMPRENANT UN VEHICULE LIQUIDE DE HAUTE VISCOSITE (84) Designated Contracting States: • GIBSON, John, W. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Sprinville, AL 35146 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • MIDDLETON, John, C. Birmingham, AL 35244 (US) (30) Priority: 13.12.2002 US 433116 P 04.11.2003 US 517464 P (74) Representative: Woods, Geoffrey Corlett J.A. Kemp & Co. (43) Date of publication of application: 14 South Square 21.09.2005 Bulletin 2005/38 Gray’s Inn London (60) Divisional application: WC1R 5JJ (GB) 10003425.5 / 2 218 448 (56) References cited: (73) Proprietor: Durect Corporation GB-A- 2 238 478 US-A- 5 266 331 Cupertino, CA 95014-4166 (US) US-B1- 6 413 536 (72) Inventors: • SULLIVANS A ET AL: "Sustained release of orally • YUM, Su, Il administered active using SABER(R) delivery Los Altos, CA 94024 (US) system incorporated into soft gelatin capsules" • SCHOENHARD, Grant PROCEEDINGS OF THE CONTROLLED San Carlos, CA 94070 (US) RELEASE SOCIETY 1998 UNITED STATES, no.
    [Show full text]
  • 1 Opioid Receptor
    Neuron, Vol. 11, 903-913, November, 1993, Copyright 0 1993 by Cell Press Cloning and Pharmacological Characterization of a Rat ~1Op ioid Receptor Robert C. Thompson, Alfred Mansour, Huda Akil, cortex, and have been shown to bind enkephalin-like and Stanley 1. Watson peptides (Mansour et al., 1988; Wood, 1988). 6 recep- Mental Health Research Institute tors are also thought to modulate several hormonal University of Michigan systems and to mediate analgesia. Ann Arbor, Michigan 48109-0720 The p receptors represent the third member of the opioid receptor family.These receptors bind morphine- like drugs and several endogenous opioid peptides, Summary including P-endorphin (derived from proopiomelano- cortin) and several members of both the enkephalin We have isolated a rat cDNA clone that displays 75% and the dynorphin opioid peptide families. These re- amino acid homology with the mouse 6 and rat K opioid ceptors have been localized in many regions of the receptors. The cDNA (designated pRMuR-12) encodes CNS, including the striatum (striatal patches), thalamus, a protein of 398 amino acids comprising, in part, seven nucleus tractus solitarius, and spinal cord (Mansour hydrophobic domains similar to those described for other et al., 1987; McLean et al., 1986; Temple and Zukin, 1987; C protein-linked receptors. Data from binding assays Wood, 1988; Mansour and Watson, 1993). p receptors conducted with COS-1 cells transiently transfected with appear to mediate the opiate phenomena classically a CMV mammalian expression vector containing the full associated with morphine and heroin administration, coding region of pRMuR-12 demonstrated p receptor including analgesia, opiate dependence, cardiovascu- selectivity.
    [Show full text]
  • CNS Drug Reviews Vol
    CNS Drug Reviews Vol. 11, No. 2, pp. 195–212 © 2005 Neva Press, Branford, Connecticut Bremazocine: A ê-Opioid Agonist with Potent Analgesic and Other Pharmacologic Properties Juanita Dortch-Carnes1 and David E. Potter2 1Department of Pharmacology/Toxicology, Morehouse School of Medicine, Atlanta, GA, USA; 2Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA Keywords: Analgesia — Bremazocine — Diuresis — Dysphoria — ê-Opioid agonists — Ocu- lar hypotension — Respiration. ABSTRACT Bremazocine is a ê-opioid receptor agonist with potent analgesic and diuretic activities. As an analgesic it is three- to four-times more potent than morphine, as determined in both hot plate and tail flick tests. Bremazocine and other benzomorphan analogs were synthe- sized in an effort to produce opiates with greater ê-opioid receptor selectivity and with minimal morphine-like side effects. Unlike morphine bremazocine is devoid of physical and psychological dependence liability in animal models and produces little or no respi- ratory depression. While bremazocine does not produce the characteristic euphoria asso- ciated with morphine and its abuse, it has been shown to induce dysphoria, a property that limits its clinical usefulness. Similarly to morphine, repeated administration of bremazo- cine leads to tolerance to its analgesic effect. It has been demonstrated that the marked di- uretic effect of bremazocine is mediated primarily by the central nervous system. Because of its psychotomimetic side effects (disturbance in the perception of space and time, abnormal visual experience, disturbance in body image perception, de-personaliza- tion, de-realization and loss of self control) bremazocine has limited potential as a clinical analgesic.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Dextrorphan Binds to Opioid Receptors in Guinea-Pig Brain Membranes And
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 1629-1632, March 1990 Pharmacology Dextrorphan binds to opioid receptors in guinea-pig brain membranes and is an antagonist at opioid receptors in myenteric plexus (binding/guinea-pig ileum/levorphanol/stereoselectivity) AVRAM GOLDSTEIN AND ASHA NAIDU Department of Pharmacology, Stanford University, Stanford, CA 94305 Contributed by Avram Goldstein, December 11, 1989 ABSTRACT Dextrorphan (+)-tartrate, purified by re- LaRoche); [D-Ala,MePhe4,Gly-ol5]enkephalin (DAGO; Pe- peated crystallization to remove all traces of the enantiomer ninsula Laboratories) (2); trans-3,4-dichloro-N-methyl- levorphanol, binds to IL, 6, and K sites on guinea-pig brain N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methane- membranes with lower affinities (by a factor of400-3200) than sulfonate (U50,488; Upjohn) (3); (-)-naloxone hydrochloride levorphanol. In the guinea-pig ileum myenteric plexus longi- (NAL; Endo Laboratories, New York); normorphine hydro- tudinal muscle preparation (GPI), dextrorphan, at 100-200 chloride (NOR) and (+)-naloxone hydrochloride (National ,uM, inhibits the electrically stimulated twitch, but this action Institute on Drug Abuse); N-methyl-D-aspartic acid (NMDA), is not blocked or reversed by naloxone; both (+)- and (-)- aminophosphonovalerate, norepinephrine (levarterenol), at- naloxone produce similar non-opioid twitch inhibition at com- ropine, and eserine (physostigmine) (Sigma). parable concentrations. At 10-20 jaM, dextrorphan' blocks and Preparation ofDEXp. [3H]LEV (Ro 1-5431/701, Hoffmann- reverses the twitch inhibition due to ,u and KWagonists, but the LaRoche; 17.4 Ci/mmol; 1 Ci = 37 GBq) was purified' by blockade can be overcome only partially by increasing the preparative reversed-phase HPLC (Waters, C18 AgBondaPak, agonist concentration.
    [Show full text]
  • Evaluation of Biased and Balanced Salvinorin a Analogs in Preclinical Models of Pain
    fnins-14-00765 July 18, 2020 Time: 20:26 # 1 ORIGINAL RESEARCH published: 21 July 2020 doi: 10.3389/fnins.2020.00765 Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain Kelly F. Paton1, Andrew Biggerstaff1, Sophia Kaska2, Rachel S. Crowley3, Anne C. La Flamme1,4, Thomas E. Prisinzano2,3 and Bronwyn M. Kivell1* 1 School of Biological Sciences, Centre for Biodiscovery, Faculty of Science, Victoria University of Wellington, Wellington, New Zealand, 2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, United States, 3 Department of Medicinal Chemistry, School of Pharmacy, The University of Kansas, Lawrence, KS, United States, 4 Malaghan Institute of Medical Research, Wellington, New Zealand In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential. Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is limited by the short duration of action and aversive side effects. Biasing KOPr signaling toward G-protein activation has been highlighted as a key cellular mechanism to reduce the side effects of KOPr agonists. The present study investigated KOPr signaling bias and the acute antinociceptive effects and side effects of two novel analogs of SalA, Edited by: 16-Bromo SalA and 16-Ethynyl SalA. 16-Bromo SalA showed G-protein signaling bias, Dominique Massotte, whereas 16-Ethynyl SalA displayed balanced signaling properties. In the dose-response Université de Strasbourg, France tail-withdrawal assay, SalA, 16-Ethynyl SalA and 16-Bromo SalA were more potent than Reviewed by: Mariana Spetea, the traditional KOPr agonist U50,488, and 16-Ethynyl SalA was more efficacious.
    [Show full text]
  • Long-Term Visceral Hypersensitivity Following Induction of Chemical
    Research Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.30.005024 Long-Term Visceral Hypersensitivity Following Induction of Chemical Colitis is Primarily Reduced via Kappa Opiate Pathways - A Comparative Study of Different Opioidergic Subtypes D Engel1,2, M Stutz1,2, JC Miller1,2, B Flogerzi1,2, L Tovar1,2, Scheurer U1,2 and Gschossmann JM*1,2 1Department of Visceral Surgery and Medicine, Inselspital, Switzerland 2Department of Clinical Research, Inselspital, Switzerland *Corresponding author: Juergen MGschossmann, Klinikum Forchheim, Department of Internal Medicine, Krankenhausstrasse 10, D-91301 Forchheim, Germany ARTICLE INFO ABSTRACT Received: September 25, 2020 Background/Aims: Transient gastrointestinal infections frequently precede functional bowel disorders with altered visceral sensory function. The aim of our study Published: October 02, 2020 was a) to demonstrate the long-term effect of a chemically induced colitis on visceral sensory function in response to phasic colorectal distensions (CRD) and b) to analyze the impact of different opiate receptor agonists (ORA) and the NMDA antagonist ketamine on Citation: D Engel, M Stutz, JC Miller, B modulation of visceral hypersensitivity following chemical colitis in a rat model. Flogerzi, L Tovar, Scheurer U, Gschoss- mann JM. Long-Term Visceral Hypersen- Methods: In forty male Lewis rats, 6 weeks after induction of trinitrobenzene sulfonic sitivity Following Induction of Chemical acid (TNB) colitis (colitis group) versus saline (control group), electromyographic Colitis is Primarily Reduced via Kappa recordings of CRD were performed. Different ORA and/or ketamine were administered Opiate Pathways - A Comparative Study intraperitoneally. of Different Opioidergic Subtypes. Bi- Results: The chemically induced colitis was followed by persistent visceral omed J Sci & Tech Res 30(5)-2020.
    [Show full text]
  • The Kappa Opioid Agonist, Salvinorin A, Attenuates Locomotor Effects of Morphine but Not Morphine-Induced Conditioned Place Preference
    Western Michigan University ScholarWorks at WMU Master's Theses Graduate College 6-2012 The Kappa Opioid Agonist, Salvinorin A, Attenuates Locomotor Effects of Morphine but not Morphine-Induced Conditioned Place Preference Stacy Dianne Engebretson Follow this and additional works at: https://scholarworks.wmich.edu/masters_theses Part of the Psychology Commons Recommended Citation Engebretson, Stacy Dianne, "The Kappa Opioid Agonist, Salvinorin A, Attenuates Locomotor Effects of Morphine but not Morphine-Induced Conditioned Place Preference" (2012). Master's Theses. 67. https://scholarworks.wmich.edu/masters_theses/67 This Masters Thesis-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Master's Theses by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE KAPPA OPIOID AGONIST, SALVINORIN A, ATTENUATES LOCOMOTOR EFFECTS OF MORPHINE BUT NOT MORPHINE-INDUCED CONDITIONED PLACE PREFERENCE by Stacy Dianne Engebretson A Thesis Submitted to the Faculty of the Graduate College in partial fulfillment of the requirements for the Degree of Master of Arts Department of Psychology Advisor: Lisa E. Baker, Ph. D. Western Michigan University Kalamazoo, Michigan June 2012 THE GRADUATE COLLEGE WESTERN MICHIGAN UNIVERSITY KALAMAZOO, MICHIGAN Date May 23, 2012 WE HEREBY APPROVE THE THESIS SUBMITTED BY Stacy Dianne Engebretson ENTITLED The Kappa Opioid Agonist, Salvinorin A, Attenuates Locomotor Effects of Morphine but Not Morphine-Induced Conditioned Place Preference. AS PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Arts Psychology (Department) Thesis Committee Behavior Analysis ®4o^Q& (Program) Alan D. Poling, Ph.! Thesis Committee Memf APPROVED s$AM>sr\ Date UlUL U\l Dean of>f The Graduate College THE KAPPA OPIOID AGONIST, SALVINORIN A, ATTENUATES LOCOMOTOR EFFECTS OF MORPHINE BUT NOT MORPHINE-INDUCED CONDITIONED PLACE PREFERENCE Stacy Dianne Engebretson, M.A.
    [Show full text]
  • Chemistry of Compounds Journal Benzomorphan Skeleton As Scaffold for Analgesic, Antiviral and Antitumoral Drugs
    www.verizonaonlinepublishing.com Vol: 1, Issue: 1 Chemistry of Compounds Journal Benzomorphan Skeleton as Scaffold for Analgesic, Antiviral and Antitumoral drugs Rita Turnaturi* and Lorella Pasquinucci Department of Drug Sciences, Medicinal Chemistry Section, University of Catania *Corresponding author: Rita Turnaturi, Department of Drug Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy; Tel: +39-0957384017; E mail: [email protected] Article Type: Short Communication, Submission Date: 26 August 2016, Accepted Date: 19 September 2016, Published Date: 27 October 2016. Citation: Rita Turnaturi and Lorella Pasquinucci (2016) Benzomorphan Skeleton as Scaffold for Analgesic, Antiviral and Antitumoral drugs. Chemi.Compol. J 1(1): 6-7. Copyright: © 2016 Rita Turnaturi and Lorella Pasquinucci. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract analgesic in phase II clinical trials that acts as a partial agonist of the mu and delta opioid receptors (MOR and DOR). Similarly, Benzomorphan core is a versatile structure. In fact, it represented Bremazocine[4] (Figure 2b) is a kappa opioid receptor (KOR) the skeleton of drugs with different mechanism of action, from agonist related to pentazocine and possesses potent and long- opioid to σ1 receptor, from antiviral to antiproliferative. lasting analgesic and diuretic effects. Alazocine ((-)-SKF-10,047, Based upon these considerations, the design, synthesis and bio- Figure 2c) [5] is the first drug discovered to act at sigma1 (σ1) logical evaluation of benzomorphan-based compounds as puta- receptor. Crobenetine[6] (Figure 2d) is a potent, selective and tive antiviral and/or antitumoral drug candidates could represent highly use-dependent Na+ channel blocker.
    [Show full text]
  • Behavioral Characterization of Opioid Mixed Agonist- Antagonists
    Drug and Alcohol Dependence, 20 (1987) 303-315 303 Elsevier Scientific Publishers Ireland Ltd. BEHAVIORAL CHARACTERIZATION OF OPIOID MIXED AGONIST- ANTAGONISTS JAMES H. WOODS and GAIL WINGER Departments of Pharmacology and Psychology, University of Michigan, Ann Arbor, MI (U.S.A.) SUMMARY The effects of agonists and partial agonists of both mu and kappa recep- tor systems are described in several behavioral tests in rhesus monkeys. Procedures measuring drug discrimination, drug self-administration, drug dependence, and drug-induced analgesia are differentially sensitive to the agonist and antagonist effects of various opioids. The sensitivity of each of the procedures may be modified by altering behavioral parameters or dose of drug used to establish the behavioral effect. Key words: Opioids - Self-administration - Drug-discrimination - Physio- logical dependence - Analgesia - Rhesus monkey INTRODUCTION ‘The term agonist-antagonist as applied to opioid analgesics and their central nervous system actions has thus come to involve two concepts: 1) the concept of multiple receptors; 2) the concept of partial agonists’ [ 11. This description of the basic attributes of opioid agonist-antagonists, also referred to as partial agonists or mixed agonist-antagonists, hints at the complex nature of these drugs and the difficulties involved in classifying them and interpreting their actions. It must be determined through which of the multiple opioid receptors any given drug exerts agonist effects. In addi- tion, the nature of its partial agonist properties, on this same or another receptor, must be described. The emphasis of the present paper is on the various procedures that have yielded information about agonist and partial agonist actions of opioids in the rhesus monkey.
    [Show full text]